INTRAVASCULAR ULTRASOUND EVALUATION OF COMPLEX BIFURCATION LESIONS TREATED WITH TRYTON SIDE-BRANCH STENT IN CONJUNCTION WITH EVEROLIMUS-ELUTING STENTS.

Slides:



Advertisements
Similar presentations
Clinical Trial Results. org ABSORB Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. Patrick W. Serruys.
Advertisements

IVUS Use during Left Main PCI improve Immediate and Long Term Outcome Where is the Evidence? E Murat Tuzcu, MD, FACC Professor of Medicine Vice Chairman.
A multicenter, randomized, prospective DKCRUSH-III study
Bifurcation stenting. Crush technique. LAD / Diagonal 68 yr old male
Www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis,
Bifurcation coronary stenting: State 0f the Art Mazhar M Khan Consultant Cardiologist Royal Victoria Hospital Belfast, N.Ireland.
BIFURCATION LESIONS Dr. Tahsin.N
29th ANNUAL SCIENTIFIC SESSIONS – SCA&I
Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)
Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.
As presented by Patrick W. Serruys, MD, PhD, FACC Principal Investigator Thoraxcentre - Erasmus University Rotterdam, The Netherlands PISCES Paclitaxel.
Tips and Pitfalls in Measurement of FFR during Bifurcation Stenting Nanjing first hospital Nanjing cardiovascular hospital Yefei Chenshaoliang Zhangjunjie.
DR ALEX CHASE REGIONAL HEART CENTRE MORRISTON SWANSEA SLIDE MATERIAL:PERSONAL COMMUNICATION WITH AUTHORS ABBOTT, BOSTON SCIENTIFIC, CORDIS, MEDTRONIC TCT.
1 SIROLIMUS-ELUTING STENTS FOR IN-STENT RESTENOSIS TREATMENT IN 278 UNSELECTED PATIENTS: INSIGHTS ON LONG-TERM OUTCOMES FROM A LARGE TWO-CENTER REGISTRY.
Disclosures The presenter has no financial involvement with the product or competing products being discussed. The presenter received travel and lodging.
The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®
Left Main Trifurcation Disease: Early and Long-Term Outcomes Of Percutaneous Coronary Intervention I.Sheiban, A.Gerasimou, F. Sciuto, P.Omedè, G. Biondi.
Maurizio Menichelli MD San Camillo Hospital, Rome ( SESAMI Trial) Maurizio Menichelli Presenter Disclosure Information Nothing to Disclose Randomized trial.
Intravascular ultrasound does not provide any significant clinical benefit for percutaneous coronary intervention of bifurcation lesions Giuseppe Biondi.
British Bifurcation Coronary Study Objective:To compare the outcome of 2 treatment strategies for bifurcation lesions. Study:Multicenter, randomized trial.
TCT 2012 Revascularization Strategies for Complex Left Main Disease and Left Coronary Ostial Disease Alfredo E. Rodriguez, MD, PhD, FACC, FSCAI Centro.
左主干分叉病变治疗策略的选择 Left main bifurcation: what is the best choice? Lei Ge, MD Department of Cardiology, Zhongshan Hospital, Fudan University.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
Two-Year Outcomes After Everolimus- or Sirolimus- Eluting Stents in Patients With Coronary Artery Disease in the ISAR-TEST 4 Trial Robert A. Byrne, Adnan.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
LONG-TERM CLINICAL OUTCOMES AFTER REPEAT DRUG-ELUTING STENT IMPLANTATION FOR IN DRUG-ELUTING STENT RESTENOSIS. C. Graidis, D. Dimitriadis, A. Ntatsios,
Case report of FFR for bifurcation Nanjing first hospital Nanjing heart center Yefei chenshaoliang.
Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)
Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.
Lianglong Chen MD PhD FACC
“Randomized Comparison between Sirolimus (Cypher)/Sirolimus-analogous (Xience; Promus) vs. Paclitaxel (Taxus vs.Costar) Eluting Stents in Coronary Lesions:
Www. Clinical trial results.org Cypher sirolimus-eluting stent Primary Endpoint:  In-stent and late lumen loss at 9 months (determined by QCA) Secondary.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
1 Superiority Of A Simple Stenting Strategy For Coronary Bifurcation Lesions In The Drug-Eluting Stent Era: Evidence From A Meta-Analysis Of 1141 Patients.
J Hermiller MD 1 Bifurcation Lesion Treatment Option: Insights From Clinical Literature James Hermiller, MD, FACC, FSCAI St Vincent Medical Group St Vincent.
Tryton Pivotal IDE-RCT Results Implications For Everyday Practice Integrating Dedicated Technology Antonio L. Bartorelli, FACC, FESC Centro Cardiologico.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Columbia University Medical Center Cardiovascular Research Foundation New York City, NY Akiko Maehara, MD Use of IVUS Reduces Stent Thrombosis and Myocardial.
Ms. Leonardo Roever Coronary Stents. Coronary Artery Disease Leading cause of death in United States for men and women Caused by buildup of plaque in.
Influence of a Pressure Gradient Distal to Implanted Bare-Metal Stent on In-Stent Restenosis After Percutaneous Coronary Intervention Lisette Okkels Jensen,
Results From the MISSION! Intervention Study Sirolimus-Eluting Stents Vs Bare-Metal Stents in Patients With STEMI : 9-Month Angiographic and Intravascular.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Severe Neointimal Hyperplasia of Neoplastic Carina.
Intravascular ultrasound (IVUS) in percutaneous coronary intervention – summary of key articles While angiography is routinely used for assessment of CAD,
Intravascular ultrasound (IVUS) in the treatment of long and diffuse lesions– summary of key articles Prepared by Radcliffe Cardiology 21 November2016.
Will we ever see a dedicated bifurcated DES in clinical practice?
Bifurcation Management Update:
(DES)+BVS +DCB for long diffuse LAD disease
How to Handle a Complex Bifurcation Lesion
Strategy planning in coronary bifurcation stenting
Volume 54, Issue 1, Pages (August 2009)
The Tryton Bifurcation Trial:
TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.
Stenting of Coronary Arteries in Non Stress/Benestent Disease
Impact of calcium on procedural and clinical outcomes in lesions treated with bioresorbable vascular scaffolds - A prospective BRS registry study  Jiang.
TAXUS II and IV: two-year follow-up
SKS Technique Clinical Case
BBK II Trial design: Patients undergoing a two-stent approach for a de novo bifurcation lesion were randomized in a 1:1 fashion to either culotte stenting.
Incidence And Management Of Restenosis After Treatment Of Unprotected Left Main Disease With Drug-Eluting Stents: 70 Restenotic Cases From A Cohort Of.
Giuseppe Biondi Zoccai, MD
Presented at ACC 2003 Late Breaking Clinical Trials
SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.
Bifurcation Disease: Simulation Training Curriculum
Main branch restenosis at 1 year
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
SMART-STRATEGY Trial design: Patients with a bifurcation coronary lesion were randomized to a conservative strategy (n = 128) vs. an aggressive strategy.
ORAL CILOSTAZOL TREATMENT PREVENTS RESTENOSIS AND MAJOR ADVERSE CLINICAL EVENTS AFTER DRUG-ELUTING STENT IMPLANTATION: EVIDENCE FROM A META-ANALYSIS G.
Presented at TCT 2006.
Maintenance of Long-Term Clinical Benefit with
MACE: Death, MI or TLR at 5 years
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
Presentation transcript:

INTRAVASCULAR ULTRASOUND EVALUATION OF COMPLEX BIFURCATION LESIONS TREATED WITH TRYTON SIDE-BRANCH STENT IN CONJUNCTION WITH EVEROLIMUS-ELUTING STENTS D. Trabattoni, MD, FACC; F. Fabbiocchi, MD; P. Montorsi, MD; S. Galli, MD; P. Ravagnani, MD; A. Lualdi, MD; L. Grancini, MD; A.L. Bartorelli, MD, FACC Centro Cardiologico Monzino, IRCCS, University of Milan, Milan - Italy 6-Month Clinical F/U (n=9) MACE: 1 death days in recent large anterior STEMI) TLR: 0 TVR: 1 MV (disease progression on LM-LAD) 6-Month angiographic F/U (n= 8 [80%]) In-stent restenosis at 6 months Main Vessel 0% Side branch: 0% When used in conjunction with a DES, the Tryton stent is associated with good clinical outcome and low restenosis rate These preliminary IVUS results show: - Complete coverage of side branch ostium - Complete stent expansion - Large final area - High symmetry (Dmin/Dmax) of the Tryton - This may contribute to the low restenosis observed in Tryton I These preliminary data suggest that the Tryton stent approach provides a reliable and reproducible strategy to stent the SB and its origin The authors have nothing to disclose D1 LAD 6-mos Follow-up D1 LAD Post Tryton Stent Implantation Restenosis of bifurcation lesions remains high even in the DES era, particularly with the two-stent technique Crush-stent technique offers complete coverage of SB but postprocedural IVUS imaging showed*: MSA significantly smaller in SB than in MV SB stent frequently underexpanded, tipically at the ostium MSA of SB <4 mm 2 in 55%, <5 mm 2 in 90% Incomplete SB or MV stent apposition in the crush area (60%) Stent underexpansion not detected by angiography BIFURCATION LESIONS *Costa et al. JACC 2005; 46: BACKGROUND The Tryton Side-Branch Stent was designed to treat complex bifurcation lesions (BL). The results of FIM study demonstrated safety and feasibility and low restenosis rate at 6-month angiographic follow- up. PURPOSE: To evaluate clinical outcome, restenosis rate and ultrasound results after BL treatment with the Tryton Stent. TRYTON vs. CRUSH Postprocedural IVUS Data SB Ostium MSA ±1.0 SB Distal MSA ±2.3 SB stent CSA < 4 mm 2 21%55% SB stent CSA < 5 mm 2 66%90% SB Dmin/D max0.83N/A Costa et al. JACC 2005; 46: TRYTON TRYTONN=10 CRUSH* CRUSH*N=15 * Non LM lesions Study Design: Single-center prospective study (n=30 patients) Six-month angiographic and IVUS F/U Postintervention and F/U IVUS analysis in both branches 40-MHz IVUS catheter (BSC) advanced 10 mm beyond and proximal to the stented segments IVUS imaging recorded during automated transducer pullback (0.5 mm/s) onto a CD rom for off-line analysis HYBRID STRATEGY Tryton Side- Branch Stent (BMS) Main-Vessel Stent (DES) PRELIMINARY RESULTS MEDINA Classification 1,1,1 n=9 1,1,0 n=1 0,1,0 n=1 11 patients (8 men, 3 women, mean age 64±12 yrs)11 patients (8 men, 3 women, mean age 64±12 yrs) 10 LAD-Diag and 1 LCx-OM10 LAD-Diag and 1 LCx-OM All Tryton stents correctly implanted in SB and all DES (Xience V) properly placed in MVAll Tryton stents correctly implanted in SB and all DES (Xience V) properly placed in MV Kissing balloon performed in all casesKissing balloon performed in all cases 100% angio and procedural success100% angio and procedural success IVUS imaging of all SB and of 10/11 MVIVUS imaging of all SB and of 10/11 MV CONCLUSIONS IVUS IMAGES Cobalt Chromium alloy Cobalt Chromium alloy Strut thickness= (85 µm) Strut thickness= (85 µm) Stent length= 18 mm Stent length= 18 mm Angles: all Angles: all Generous landing zone Generous landing zone (positioning tolerance) (positioning tolerance) Rapid exchange catheter Rapid exchange catheter Single-wire tracking Single-wire tracking No need for rotational orientation No need for rotational orientation Low Profile Low Profile - 5Fr guide compatible Balloon Semi-compliant Balloon Semi-compliant TRYTON stent CHARACTERISTICS DELIVERY SYSTEM DELIVERY SYSTEM